Gary Mason

3.6k total citations
32 papers, 725 citations indexed

About

Gary Mason is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Gary Mason has authored 32 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Gary Mason's work include Prostate Cancer Treatment and Research (14 papers), PARP inhibition in cancer therapy (12 papers) and Glioma Diagnosis and Treatment (6 papers). Gary Mason is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), PARP inhibition in cancer therapy (12 papers) and Glioma Diagnosis and Treatment (6 papers). Gary Mason collaborates with scholars based in United States, France and Australia. Gary Mason's co-authors include Laura Liberman, D. David Dershaw, Elizabeth A. Morris, Ian F. Pollack, Ashok Panigrahy, Regina I. Jakacki, Hideho Okada, Lisa H. Butterfield, Ronald L. Hamilton and Daniel P. Normolle and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Gary Mason

31 papers receiving 715 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary Mason United States 12 312 295 170 147 143 32 725
Heidi V.N. Küsters‐Vandevelde Netherlands 16 250 0.8× 319 1.1× 50 0.3× 136 0.9× 199 1.4× 39 796
María Vieito Spain 16 510 1.6× 256 0.9× 90 0.5× 189 1.3× 273 1.9× 100 907
Harm Westdorp Netherlands 14 439 1.4× 140 0.5× 102 0.6× 36 0.2× 175 1.2× 43 696
Ross Carruthers United Kingdom 12 414 1.3× 170 0.6× 82 0.5× 217 1.5× 352 2.5× 21 766
Taishi Takahara Japan 16 374 1.2× 130 0.4× 43 0.3× 71 0.5× 164 1.1× 61 751
Alexandra S. Zimmer United States 13 815 2.6× 344 1.2× 70 0.4× 157 1.1× 365 2.6× 24 1.1k
Milos J. Janicek United States 9 299 1.0× 125 0.4× 102 0.6× 140 1.0× 172 1.2× 18 592
Macarena I. de la Fuente United States 13 122 0.4× 79 0.3× 76 0.4× 300 2.0× 153 1.1× 36 510
Xianxin Qiu China 16 190 0.6× 242 0.8× 108 0.6× 155 1.1× 329 2.3× 46 790
Claudio Dansky Ullmann United States 14 398 1.3× 136 0.5× 54 0.3× 39 0.3× 275 1.9× 26 797

Countries citing papers authored by Gary Mason

Since Specialization
Citations

This map shows the geographic impact of Gary Mason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Mason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Mason more than expected).

Fields of papers citing papers by Gary Mason

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Mason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Mason. The network helps show where Gary Mason may publish in the future.

Co-authorship network of co-authors of Gary Mason

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Mason. A scholar is included among the top collaborators of Gary Mason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Mason. Gary Mason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
N., Kim, Neil Fleshner, Vincenzo Emanuele Chiurì, et al.. (2023). Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results. The Oncologist. 28(5). e309–e312. 11 indexed citations
4.
Smith, Matthew R., Shahneen Sandhu, Daniel J. George, et al.. (2023). Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects. Journal of Managed Care & Specialty Pharmacy. 29(7). 758–768. 2 indexed citations
5.
6.
7.
8.
Drake, Charles G., Russell K. Pachynski, Sumit K. Subudhi, et al.. (2021). Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 25(2). 219–228. 28 indexed citations
9.
10.
Brahmer, Julie R., Melissa L. Johnson, Manuel Cobo, et al.. (2020). JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies. JTO Clinical and Research Reports. 2(2). 100103–100103. 23 indexed citations
11.
Brahmer, Julie R., Melissa L. Johnson, Manuel Cobo, et al.. (2019). Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.. Journal of Clinical Oncology. 37(15_suppl). 9093–9093. 2 indexed citations
12.
Ceschin, Rafael, Stefan Blüml, Gary Mason, et al.. (2016). Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors. Neuroimaging Clinics of North America. 27(1). 155–166. 6 indexed citations
13.
Pollack, Ian F., Regina I. Jakacki, Lisa H. Butterfield, et al.. (2016). Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. Journal of Neuro-Oncology. 130(3). 517–527. 53 indexed citations
14.
Pollack, Ian F., Regina I. Jakacki, Lisa H. Butterfield, et al.. (2016). Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro-Oncology. 18(8). 1157–1168. 70 indexed citations
15.
Mason, Gary, et al.. (2015). The Role of Intra-Group Consensus-Building in Disarming Militant Groups in Northern Ireland. MURAL - Maynooth University Research Archive Library (National University of Ireland, Maynooth). 2(1). 232–241.
16.
Ho, Cheng‐Ying, Bret C. Mobley, Heather Gordish‐Dressman, et al.. (2015). A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. Acta Neuropathologica. 130(4). 575–585. 40 indexed citations
17.
Yang, Rui, Sajida Piperdi, Yue Zhang, et al.. (2015). Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-β as Involved in the Pathogenesis of Osteosarcoma. Clinical Orthopaedics and Related Research. 474(1). 178–189. 20 indexed citations
18.
Mason, Gary, LeLe Aung, Paul A. Meyers, et al.. (2013). Quality of Life Following Amputation or Limb Preservation in Patients with Lower Extremity Bone Sarcoma. Frontiers in Oncology. 3. 210–210. 57 indexed citations
19.
Mason, Gary, LeLe Aung, Paul A. Meyers, et al.. (2007). Quality of life following amputation or limb salvage in patients with lower extremity sarcoma. Journal of Clinical Oncology. 25(18_suppl). 19530–19530. 2 indexed citations
20.
Liberman, Laura, Gary Mason, Elizabeth A. Morris, & D. David Dershaw. (2006). Does Size Matter? Positive Predictive Value of MRI-Detected Breast Lesions as a Function of Lesion Size. American Journal of Roentgenology. 186(2). 426–430. 144 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heidi V.N. Küsters‐Vandevelde Breakdown of academic impact, for papers by María Vieito Breakdown of academic impact, for papers by Harm Westdorp Breakdown of academic impact, for papers by Ross Carruthers Breakdown of academic impact, for papers by Taishi Takahara Breakdown of academic impact, for papers by Alexandra S. Zimmer Breakdown of academic impact, for papers by Milos J. Janicek Breakdown of academic impact, for papers by Macarena I. de la Fuente Breakdown of academic impact, for papers by Xianxin Qiu Breakdown of academic impact, for papers by Claudio Dansky Ullmann
Rankless by CCL
2026